Clinical Trials Directory

Trials / Completed

CompletedNCT00684346

18FDG-PET Imaging to Detect Changes in Airways Inflammation in Cystic Fibrosis Patients

A Pilot Study of 18FDG-PET Imaging to Detect Changes in Airways Inflammation in Cystic Fibrosis Patients After Treatment for a Pulmonary Exacerbation

Status
Completed
Phase
Phase 3
Study type
Interventional
Enrollment
20 (actual)
Sponsor
The Hospital for Sick Children · Academic / Other
Sex
All
Age
6 Years – 18 Years
Healthy volunteers
Not accepted

Summary

The purpose of this study is to determine if 18Fluorodeoxyglucose (FDG) Positron Emission Tomography (PET) imaging can detect changes in airways inflammation in Cystic Fibrosis (CF) patients after treatment for a pulmonary exacerbation.

Detailed description

Neutrophils play a key role in the pathogenesis of CF lung disease. We know that neutrophilic inflammation is related to a decline in pulmonary function. Therefore, early anti-inflammatory intervention is an opportunity to slow this irreversible pulmonary destruction. However, the development of sensitive, non-invasive diagnostic tools of airways inflammation is essential to the study and implementation of anti-inflammatory therapies. Our current armentarium of measures of airways inflammation is limited. BAL is invasive and not clinically acceptable as a tool for the serial measurement of inflammation. Sputum samples are highly variable and not reliable. 18FDG-PET is a promising tool because it is non invasive, has been shown to quantify the amount and location of neutrophilic inflammation and has the potential to be used to track inflammation over time. Therefore, the goal of this research study is to evaluate the ability of 18FDG -PET imaging to detect changes in airways inflammation in CF patients in response to conventional treatment for a pulmonary exacerbation

Conditions

Interventions

TypeNameDescription
OTHER18-FDGThe administered intravenous dose of 18-FDG is 0.14mCi/kg up to a maximum of 10mCi before each PET imaging scan is performed.

Timeline

Start date
2008-04-01
Primary completion
2010-04-01
Completion
2010-04-01
First posted
2008-05-26
Last updated
2018-10-05

Locations

1 site across 1 country: Canada

Source: ClinicalTrials.gov record NCT00684346. Inclusion in this directory is not an endorsement.